Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carmeseal-MD in non-ambulatory DMD
NCT03558958Phase 2Terminated
- Sponsor
- Phrixus Pharmaceuticals, Inc.
- Start
- Aug 2018
- Primary completion
- Sep 2021
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Carmeseal-MD in Duchenne muscular dystrophy (DMD), sponsored by Phrixus Pharmaceuticals, Inc.. Started Aug 2018; status: terminated.
02
Drugs
Carmeseal-MD
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03558958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03558958.